The Department of Veterans Affairs Strategic Acquisition Center Frederick awarded an Indefinite Delivery Contract to Abbott Molecular Inc. for COVID-19 testing reagents and materials. Under the contract, Abbott Molecular will provide Alinity M testing reagents and consumables to support the VA's coronavirus response efforts.
Two firm fixed price delivery orders were issued against the contract. The first order, valued at $11 million, calls for Alinity M testing reagents to be delivered to facilities in Fredericksburg, Virginia by March 2022. The second order, valued at $6.77 million, requires Abbott Molecular to supply Alinity M consumables and reagents to sites in Des Plaines, Illinois through March 2023. Combined, the delivery orders are worth approximately $17.77 million.
Funding comes from the VA's emergency COVID-19 appropriations. The reagents and materials will enable expanded coronavirus testing and monitoring within the VA healthcare system as the agency works to protect vulnerable veteran populations during the ongoing public health emergency. Performance is taking place at locations in Virginia and Illinois. Abbott Molecular is the prime contractor supporting these efforts to bolster the VA's diagnostic capacity.
Generated 1/4/24, 9:24 PM